新福菌素联合卡铂、依托泊苷治疗老年非小细胞肺癌临床疗效观察.docxVIP

新福菌素联合卡钳、依托泊昔治疗老 年非小细胞肺癌临床疗效观察 【摘要】 目的：评价国产新福菌素对 老年非小细胞肺癌的疗效和不良反应。 方法: 选取老年NSCL商例81例，随机分治疗组 43例给予新福菌素6 [I g/kg，卡钳300mg/m2 依托泊昔100 mg静脉滴注；对照组38例单 纯使用CB闵口 VP16,剂量和方法同治疗组， 21~28d为一个疗程，2~3个疗程评价疗效， 随访缓解期和生存期。结果：治疗组有效率 为5349%对照组有效率为 3158%差异有 显着性；中位缓解期分别为 6和45个月， 中位生存期分别为9和7个月，一年生存率 分别为3953脩日2632%结论：新福菌素联 合CBP VP16治疗老年 NSCLCt较好的临床 疗效及应用价值。 【关键词】 老年；非小细胞肺癌；化 疗；新福菌素；卡钳；依托泊昔 【ABSTRACT Objective:" investigate the curative effects and sideeffect of domestic drugSinoactionomycin in treating elderly nonsmall cell lung cancer (NSCLC).Methods: 81 cases with elderly NSCLC were divided into two groups randomly,43 cases in the treatment group were administrated with Sinoactionomycin 6g/kg (1~4 day) combining card platinum (CBP) 300mg/m2 (1st day), glucoside (VP16) 100 mg (1~4 or 5days) cases in the control group were only treated with CBP and vp16 and the dosage were same with that of treatment ~28 days were taken as a treatment cycle and the curative effects were studied after 2~3 relievable and survival periods were investigated as : The effectiveness for treatment troup is 5349%, effectiveness for control group is 3158%, the difference has the significance (P005); The central relievable period is 6 and 45 months respectively, and the central survival period is 9 and 7 months respectively,on year survival rate respectively is 3953% (17,/43) and 2632%(10,/38). Conclusion: Sinoactionomycin combining CBP,and VP16 has good clinical curative effect in treating elderly NSCLC and has the good clinical practice value. 【KEYWORDS Elderly; Nonsmall cell lung cancer; Chemotherapy; Sinoactionomycin; Card platinum; VP16 肺癌一直是男女癌症患者死亡的主要 因素［1］。由于非小细胞肺癌占原发性肺癌 的75%~80%50恕上的NSCLC&者确诊时年 龄超过65岁，1/3的NSCL诳确诊时年龄 超过70岁。另外，老年人脏器储备能力降 低，尤其合并慢性心肺疾病者，因此绝大多 数老年NSCLC患者在确诊时失去手术机会， 治疗主要采用以化疗为主的综合治疗， 虽然 异长春花碱、紫杉醇等新的抗癌药物的使用 取得了良好的临床效果， 但钳类和依托泊昔 联用仍是治疗NSC LC勺基本化疗方案。新福 菌素加用卡钳和 VP16治疗NSCLCg内报道 较少，为了进一步观察其临床疗效和毒性反 应，我们对我院81例老年NSCLCS者的化 疗的近期疗效进行了观察，现报告如下。 1资料和方法 11 一般资料所选81例老年患者均系经 病理组织学或细胞学证实的 NSCLC按1997 年国际抗癌联盟制定的 TNM